citalopram has been researched along with Metabolic Syndrome in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The odds ratio for carotid artery plaque corresponding to a 1 SD decrease in prolactin response, adjusted for age, race, sex, and citalopram concentration, was 1." | 1.34 | Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis. ( Flory, JD; Mackey, RH; Manuck, SB; Muldoon, MF; Pollock, BG; Sutton-Tyrrell, K, 2007) |
| "Insulin resistance was estimated by homeostasis model assessment." | 1.33 | The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. ( Flory, JD; Korytkowski, MT; Mackey, RH; Manuck, SB; Muldoon, MF; Pollock, BG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muldoon, MF | 2 |
| Mackey, RH | 2 |
| Korytkowski, MT | 1 |
| Flory, JD | 2 |
| Pollock, BG | 2 |
| Manuck, SB | 2 |
| Sutton-Tyrrell, K | 1 |
| Tsygankov, BD | 1 |
| Chazova, IE | 1 |
| Poliakova, EO | 1 |
3 other studies available for citalopram and Metabolic Syndrome
| Article | Year |
|---|---|
The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers.
Topics: Adult; Area Under Curve; Brain; Citalopram; Cross-Sectional Studies; Female; Humans; Insulin Resista | 2006 |
Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis.
Topics: Adult; Autonomic Nervous System Diseases; Biomarkers; Blood Glucose; Carotid Stenosis; Central Nervo | 2007 |
[Psychopharmacotherapy of patients with arterial hypertension complicated with metabolic disturbances and depression].
Topics: Antihypertensive Agents; Citalopram; Depression; Drug Therapy, Combination; Female; Follow-Up Studie | 2007 |